雅虎香港 搜尋

搜尋結果

1. www.thepharmaletter.com › article › eisai-divests-rights-toEisai divests rights to Myonal and Merislon for Asian market ...

   www.thepharmaletter.com › article › eisai-divests-rights-to

   • 網頁紀錄

   2022年7月11日 · 07-11-2022 Print. Japanese drug major Eisai (TYO: 4523) today announced that it has entered into an agreement to divest its rights for muscle relaxant Myonal (eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon (betahistine mesilate) in Asia to a subsidiary of Switzerland-based DKSH Holding Ltd.

2. www.acnnewswire.com › ArticleEisai to Divest Rights for Merislon and Myonal in Japan to K ...

   www.acnnewswire.com › Article

   • 網頁紀錄

   2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.

3. myhealthbox.eu › en › merislon-tablet-6mgMERISLON TABLET | myHealthbox

   myhealthbox.eu › en › merislon-tablet-6mg

   • 網頁紀錄

   2023年2月15日 · increases the blood flow in the inner ear. It relaxes the smooth muscles in the inner. ear, thereby increases the circulation. It. also improves circulation in the brain by. increasing blood flow to the brain. Thus, MERISLON ® is clinically useful for the. relief of vertigo and dizziness.

4. pj.jiho.jp › article › 247739Eisai Divests Rights to Myonal, Merislon to Swiss Firm DKSH ...

   pj.jiho.jp › article › 247739

   • 網頁紀錄

   2022年11月8日 · Eisai said on November 7 that it is divesting its rights in certain Asian markets for the muscle relaxant Myonal (eperisone) and vertigo and equilibrium disturbance treatment Merislon (betahistine mesilate) to Swiss peer DKSH Holding. Whenever an excellent ...

5. www.acnnewswire.com › press-release › englishEisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, ...

   www.acnnewswire.com › press-release › english

   • 網頁紀錄

   2022年11月7日 · Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical Friday, 29 March 2024, 15:19 JST Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture Friday, 29 March 2024, 14:32 JST

6. www.centralcharts.com › en › newsEisai to Divest Rights for Merislon and Myonal in Japan to K ...

   www.centralcharts.com › en › news

   • 網頁紀錄

   2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium 128 currency pairs AUD currency pairs CAD currency pairs CHF currency pairs EUR currency pairs GBP

7. www.farmasi-id.com › merislonMerislon | Kandungan, Indikasi, Efek Samping, Dosis, Obat ...

   www.farmasi-id.com › merislon

   • 網頁紀錄

   2024年4月6日 · Perusahaan induknya, Eisai Co. Ltd adalah perusahaan farmasi besar yang berkedudukan di Tokyo, Jepang. Perusahaan ini didirikan pada 1941 dan memiliki sekira 10 ribu karyawan. Akuisisi MGI Pharma oleh Eisai Co. Ltd pada tahun 2007 membuat perusahaan cukup kuat posisinya sebagai produsen obat-obatan onkologi yang menghasilkan produk seperti Dacogen, Aloxi, Hexalen, dan lain-lain.